On the latest #BioCenturyShow @StephenPHansen speaks with @ArrowheadPharma CEO Chris Anzalone about solving the challenge of delivering #siRNA to extra-hepatic tissues, and how breakthroughs here can enable future growth opportunities for Arrowhead $ARWR buff.ly/DThToy4

In BioCentury's Public Equity Report: After last week's IPOs fizzled somewhat in the aftermarket, City and Iambic posted double-digit gains to restart a winning streak; Aspen and Bambusa lined up in the NASDAQ queue; and more buff.ly/2wt7YMB

Valuing a preclinical biotech at $50B is a bad idea — a Perspective by @StephenPHansen, who argues that, if the rumors are true, Isomorphic Labs would require near perfect clinical execution to justify the valuation buff.ly/nN0TQWz

EMA’s CHMP backs RevMed’s first-in-class pancreatic cancer therapy. Recommendations follow speedy FDA approvals of the RAS(ON) inhibitor and Lilly’s obesity pill Foundayo orforglipron buff.ly/mKZblpR

FDA's rare disease framework initiative marks the start of a journey that it hopes will end with more consistent policies. Success will depend on rebuilding capacity depleted by DOGE cuts. buff.ly/YWUrlBc

Roche turns to Rona for ALK7-siRNA for selective fat loss, as China biotechs fuel a growing RNAi pipeline silencing ALK7 in adipocytes. buff.ly/hrzh5Ao

China’s RNAi pipeline drives dealmaking with the West. Cardiometabolic programs lead the dealmaking as China’s developers push delivery beyond the liver buff.ly/dczJKGs

In BioCentury's Management Tracks: Former Galapagos executives Paul Stoffels and Willemijn Kremer have landed at Armed Cell Therapies and taken rights to CAR T programs that had belonged to their former employer; and more buff.ly/GZalJxz

In BioCentury's Venture Report: OMass' $310M round among biggest in U.K. history for a biotech; OrbiMed's $3B pair of funds; rounds for Souffle and Altay; and more buff.ly/H9UcXW0

First human tau-lowering data from @ArrowheadPharma mark a milestone for brain shuttle–siRNA delivery. But how much tau knockdown delivers benefit without compromising normal neuronal functions remains an open question. $ARWR buff.ly/Gy5YGoj

In BioCentury's Management Tracks: Verastem introduces new CEO as it announces data, funding; plus updates from AL-S and YolTech buff.ly/1h7Rlxq

Fully autonomous labs need human know-how, not just more robots. AstraZeneca, Thermo Fisher, and Sofinnova Partners on capturing bench expertise to enable better experiments and less human intervention buff.ly/iTlNpzR

Beyond patient matching: AI’s role in reshaping trial recruitment. TriNetX, Paradigm, and Tempus tackle feasibility, enrollment workflows, and site activation through different models buff.ly/fWhTvlU

Beyond the medical record: bridging data gaps to uncover disease biology. From physicians’ notes to tissue samples, companies are building a richer picture of disease beyond oncology. buff.ly/oCDrA8f

In BioCentury's latest Management Tracks: Viking's commercial chief exits after nine months; Apogee's team reunites at Paragon Labs; and more buff.ly/kRLscs4

Turning the patient into the bioreactor: Rice University spinout Duracyte is developing implants of engineered human cells designed to produce biologics inside the body for up to a year, potentially replacing repeated injections and infusions. buff.ly/3xeqOkA

Overton confirmation battling clock, abortion politics: Sen. Hawley’s concerns about @US_FDA study of mifepristone safety add complexity to tight confirmation window buff.ly/P4mqxjK

Three celiac trial successes put dosing in the spotlight. BioCentury’s Clinical Report for Oct. 6–12 also covers ArriVent’s Phase III lung cancer miss and more buff.ly/CCfe2ry

In BioCentury's Deals Report: Viatris gains pair of marketed pain drugs, plus pipeline assets, in Pacira takeout; Biohaven and Ono in regional deal for degraders; and more buff.ly/xXHbmJK

4Q26 public markets preview: After a flat third quarter marked by slower M&A and follow-on activity, biotech investors expect a quiet year-end amid macro risks and U.S. elections, with hopes for renewed dealmaking. buff.ly/BdhHn2b